Related Experiment Video
Updated: Apr 10, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
Inhibitory effects of parthenolide on the activity of NF-κB in multiple myeloma via targeting TRAF6
Fan-Cong Kong1, Jing-Qiong Zhang2, Chen Zeng1
1Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Abstract:
This study examined the mechanism of the inhibitory effect of parthenolide (PTL) on the activity of NF-κB in multiple myeloma (MM). Human multiple myeloma cell line RPMI 8226 cells were treated with or without different concentrations of PTL for various time periods, and then MTT assay was used to detect cell proliferation. Cell cycle and apoptosis were flow cytometrically detected. The level of protein ubiquitination was determined by using immunoprecipitation. Western blotting was employed to measure the level of total protein ubiquitination, the expression of IκB-α in cell plasma and the content of p65 in nucleus. The content of p65 in nucleus before and after PTL treatment was also examined with immunofluorescence. Exposure of RPMI 8226 cells to PTL attenuated the level of ubiquitinated Nemo, increased the expression of IκB-α and reduced the level of p65 in nucleus, finally leading to the decrease of the activity of NF-κB. PTL inhibited cell proliferation, induced apoptosis and blocked cell cycle. Furthermore, the levels of ubiquitinated tumor necrosis factor receptor-associated factor 6 (TRAF6) and total proteins were decreased after PTL treatment. By using Autodock software package, we predicted that PTL could bind to TRAF6 directly and tightly. Taken together, our findings suggest that PTL inhibits the activation of NF-κB signaling pathway via directly binding with TRAF6, thereby suppressing MM cell proliferation and inducing apoptosis.
Insights
Parthenolide (PTL) inhibits nuclear factor-kappa B (NF-κB) signaling in multiple myeloma (MM) by binding to TRAF6. This mechanism suppresses MM cell proliferation and induces apoptosis.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Nuclear factor-kappa B (NF-κB) signaling is crucial in multiple myeloma (MM) pathogenesis.
- Parthenolide (PTL) is a compound with potential anti-cancer properties.
- Understanding PTL's mechanism in MM is vital for therapeutic development.
Purpose of the Study:
- To elucidate the inhibitory mechanism of PTL on NF-κB activity in MM.
- To investigate PTL's effects on MM cell proliferation, cell cycle, and apoptosis.
- To determine the direct molecular target of PTL in the NF-κB pathway.
Main Methods:
- Human multiple myeloma RPMI 8226 cells were treated with PTL.
- Cell proliferation was assessed using MTT assay.
- Cell cycle and apoptosis were analyzed by flow cytometry.
- Protein ubiquitination, IκB-α, and p65 levels were measured by immunoprecipitation and Western blotting.
- Immunofluorescence was used to examine p65 localization.
- Autodock software predicted PTL-TRAF6 binding.
Main Results:
- PTL treatment decreased ubiquitinated Nemo and TRAF6 levels.
- PTL increased IκB-α expression and reduced nuclear p65.
- NF-κB activity was inhibited by PTL.
- PTL suppressed MM cell proliferation, induced apoptosis, and blocked cell cycle progression.
- PTL was predicted to bind directly and tightly to TRAF6.
Conclusions:
- PTL inhibits NF-κB activation by directly binding to TRAF6.
- This interaction leads to the suppression of MM cell proliferation.
- PTL effectively induces apoptosis in multiple myeloma cells, suggesting therapeutic potential.
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
NF-kB-dependent Signaling Pathway
TGF - β Signaling Pathway
Drugs that Stabilize Microtubules
Targeted Cancer Therapies
There are several types of targeted therapies against...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...

